"
EGFR Expression Is Unreliable to Decide for Cetuximab Treatment in Patients with Metastatic Colorectal Cancer: Results from “ERBITUX-OUEST”"
written by Jean-Philippe Metges, Erick Gamelin, Alain Volant, Olivier Capitain, Jean-François Ramée, Jean-Luc Raoul, Jean-Yves Douillard, Pierre-Luc Etienne, Isabelle Cumin, Olivier Dupuis, Roger Faroux, Marie-Aude Coulon, Philippe Deguiral, Karine Bideau, Nacr Eddine Achour, Alain Gourlaouen, Corinne Alleaume, Annie Wdowik, Laurent Miglianico, Yann Touchefeu, Vincent Klein, Alain Penchet, Ludovic Rosenfeld, Daniel Martin, Claire Stampfli, Jean-Jacques Auger, Alain Bargain, Murielle Broyer-Petit, Jérome Chettrit, Louis-Rémi De Ybarlucea, Serge Eloit, Pierre Marie Girardot, Nathalie Heresbach, Christian Laboisse, Eric Lavoine, Gilles Lemasson, Claire Magois, Sophie Michalak, Norbert Padilla, Joseph Politis, Frédéric Staroz, Bruno Turlin, Arnaud Uguen, Viorel Vasiliu, Véronique Verriele, Fanny Marhuenda, Delphine Déniel Lagadec, Christian Riché, Françoise Grudé,
published by
Open Journal of Internal Medicine,
Vol.6 No.2, 2016
has been cited by the following article(s):
|
[1]
|
Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis
BMC Clinical Pathology,
2019
DOI:10.1186/s12907-019-0085-8
|
|
|
|